Smoking cessation medication prescriptions in patients with T2DM and TUD (without obesity)
(Comparision between matched semaglutide vs other anti−diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
1,302	semaglutide	insulins	54 (4.1%)	148 (11.4%)	−7.2% (−9.3%, −5.2%)		0.32 (0.23−0.44)
1,305	semaglutide	metformin	54 (4.1%)	85 (6.5%)	−2.4% (−4.1%, −0.7%)		0.61 (0.43−0.85)
1,283	semaglutide	DPP−4i	51 (4.0%)	109 (8.5%)	−4.5% (−6.4%, −2.7%)		0.45 (0.32−0.62)
1,293	semaglutide	SGLT2i	54 (4.2%)	98 (7.6%)	−3.4% (−5.2%, −1.6%)		0.52 (0.37−0.73)
1,292	semaglutide	SU	52 (4.0%)	95 (7.4%)	−3.3% (−5.1%, −1.5%)		0.52 (0.37−0.73)
1,033	semaglutide	TZD	41 (4.0%)	62 (6.0%)	−2.0% (−3.0%, −0.2%)		0.62 (0.42−0.93)
1,268	semaglutide	other GLP−1RAs	52 (4.1%)	75 (5.9%)	−1.8% (−3.5%, −0.1%)		0.66 (0.47−0.95)

Hazard Ratio (HR)

0.30 0.40 0.60 0.80 2.0 3.00